Preferred Label : Lumasiran;
UNII : RZT8C352O1;
CAS number : 1834610-13-7;
NCI Metathesaurus CUI : CL1382379;
Origin ID : C170137;
UMLS CUI : C5418443;
Currated CISMeF NLP mapping
Manual BTNT mappings - CISMeF
Semantic type(s)
UMLS correspondences (same concept)
concept_is_in_subset
https://ansm.sante.fr/tableau-atu-rtu/lumasiran-94-5-mg-0-5-ml-solution-injectable
2021
false
false
false
France
French
lumasiran
summary of product characteristics
package leaflet
guidelines for drug use
Lumasiran
primary hyperoxaluria type 1
lumasiran
hyperoxaluria, primary
---
https://www.has-sante.fr/jcms/p_3266578/fr/oxlumo-94-5-mg/0-5-ml-lumasiran
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
lumasiran
Lumasiran
injections, subcutaneous
hyperoxaluria, primary
rna, small interfering
renal agents
orphan drug production
adult
adolescent
child
aged
lumasiran
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/oxlumo
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
Lumasiran
Lumasiran
hyperoxaluria, primary
lumasiran
product surveillance, postmarketing
orphan drug production
injections, subcutaneous
Primary hyperoxaluria type 1
pregnancy
breast feeding
adult
adolescent
child
rna, small interfering
rna, small interfering
drug evaluation, preclinical
renal agents
lumasiran
---